Exact Imaging Reports Strong Momentum Driven by Commercial Execution and Clinical Validation in 2025

New sales model, expanded evidence base, NCCN guideline inclusion, and growing customer adoption reinforce the value of the ExactVu™ micro-ultrasound platform

MARKHAM, Ontario--(BUSINESS WIRE)--Exact Imaging, a global leader in high-resolution micro-ultrasound systems for prostate cancer, today reported strong business momentum in calendar year 2025, reflecting progress across commercial execution, clinical validation, and market adoption.

During the year, the company implemented a new sales model, expanded the clinical evidence supporting micro-ultrasound–guided prostate imaging, achieved inclusion in leading clinical guidelines, and added new customers across key markets. Together, these developments continue to drive adoption of Exact Imaging’s ExactVu™ micro-ultrasound platform and strengthen commercial traction.

“2025 marked an important year of execution for Exact Imaging,” said Randy AuCoin, chief executive officer of Exact Imaging. “We reinforced our commercial foundation while advancing the clinical evidence supporting ExactVu. New customer wins and upcoming 2026 guideline recognition underscore the durability of our growth strategy.”

Beginning in July 2025, Exact Imaging transitioned to a direct sales model in the United States, expanding its installed base of independent physician practices, academic medical centers, U.S. Department of Veterans Affairs and integrated delivery networks, and improving sales visibility entering 2026. Internationally, Exact Imaging continued to accelerate growth across key international markets through new distributor partnerships and an expanding installed base, driving increased adoption and additional system placements worldwide.

Exact Imaging also strengthened its clinical foundation, surpassing 100 peer-reviewed publications supporting micro-ultrasound for prostate imaging, including screening, active surveillance, targeted biopsy, and treatment applications. This includes a publication in JAMA demonstrating that ExactVu micro-ultrasound is non-inferior to MRI fusion biopsy for the detection of clinically significant prostate cancer.

Further validating this body of evidence, the National Comprehensive Cancer Network^® (NCCN^®) included micro-ultrasound in its 2026 Clinical Practice Guidelines for the Early Detection of Prostate Cancer, recognizing non-inferiority to multiparametric MRI (mpMRI) and mpMRI fusion-guided biopsy.

“The inclusion of micro-ultrasound in NCCN’s internationally recognized guidelines reflects growing clinical confidence and provides urologists with a guideline-supported diagnostic option,” added AuCoin. “We expect this recognition to further support adoption across a wide range of care settings.”

For more information, visit: www.exactimaging.com/exactvu-micro-ultrasound-system